Stereotaxis, Inc. (STXS) Company Overview

What does Stereotaxis do?

Stereotaxis, Inc. is a medical-technology company listed on NYSE American as STXS. It develops robotic systems, catheters, software, and information infrastructure for minimally invasive endovascular procedures, especially cardiac electrophysiology. Its Robotic Magnetic Navigation platform uses computer-controlled magnetic fields to steer a flexible catheter tip inside the heart, replacing much of the manual pushing and rotation performed at the patient’s bedside.

The strategic premise is that digital control can make complex procedures more precise, reproducible, and remotely operable. According to the 2025 Form 10-K, hundreds of electrophysiologists at more than 100 hospitals have treated over 150,000 patients with the technology, supported by more than 500 clinical publications. That is a meaningful installed base, but still a specialized small-cap footprint.

Where does the company fit in the procedure room?

Stereotaxis sits between imaging, mapping, ablation, and hospital workflow systems. The robot controls catheter direction; software organizes procedure data; proprietary devices perform mapping or ablation; and service teams support installations over many years. The official product portfolio includes Genesis and GenesisX robots, Synchrony and SynX information tools, and MAGiC mapping and ablation catheters. Owning more of this stack is intended to increase recurring procedure economics.

How does Stereotaxis make money?

The business combines capital-equipment sales with recurring revenue. A hospital buys a robotic system and installation, then can generate continuing revenue through disposable catheters, service contracts, accessories, and software. The model resembles an installed-base-plus-consumables strategy, but current recurring gross profit does not yet cover the operating expense base.

Which revenue stream carries the better economics?

In FY2025, systems produced $10.2 million of revenue at an approximately 21.5% gross margin. Disposables, service, and accessories produced $22.2 million at an approximately 67.1% gross margin. Recurring activities therefore supplied most gross profit while representing roughly two-thirds of revenue.

Which products and revenue streams matter most?

Why is the catheter transition strategically important?

Johnson & Johnson’s supply obligation ended on December 31, 2025, making Stereotaxis-owned MAGiC catheters both an opportunity and an execution risk. MAGiC received U.S. clearance in January 2026, and the first-quarter 2026 results said it was in use at multiple U.S. and European sites. Management targeted production capacity approaching 500 catheters per month by year-end 2026.

Can software widen the addressable market?

Synchrony received European clearance in October 2025 and U.S. clearance in April 2026. It consolidates lab information and control, while SynX supports cloud-based monitoring, training, and service. Management said Synchrony could be placed without a robot in the FDA clearance announcement, creating a lower-friction entry point into non-robotic labs.

What did Stereotaxis’s latest quarter show?

The quarter ended March 31, 2026 showed the transition cost of replacing legacy catheter supply while launching new products. Revenue declined, but gross margin improved because the mix contained less low-margin system revenue. The result is analytically mixed: commercial momentum was not yet visible in reported sales, while the margin structure offered a preview of what a more recurring mix could look like.

What changed inside revenue and expense?

How did Stereotaxis evolve into an endovascular robotics platform?

The current strategy reflects a sequence of shifts: magnetic navigation, a smaller robot, proprietary devices, workflow software, and a second robotic modality through Robocath.

1. 2004
   Nasdaq listing provided access to public financing.
2. 2016
   A move to OTCQX reflected restructuring and weak scale.
3. 2019
   NYSE American restored a national-exchange listing.
4. 2020–2023
   Genesis modernized RMN with a smaller, digital architecture.
5. July 2024
   APT added disposable-device design and manufacturing capability.
6. 2025–2026
   GenesisX, MAGiC, and Synchrony completed the core product stack.
7. July 2026
   Robocath expanded the company into broader endovascular intervention.

What did the Robocath acquisition change?

The completed transaction added R-One technology used in Europe and China and widened the strategy beyond electrophysiology. The official completion announcement described Robocath as integrated into Stereotaxis. Consideration included about $20 million in cash and stock plus up to $25 million of contingent payments. The deal adds a complementary robot, but also integration risk and dilution.

What gives Stereotaxis a competitive advantage?

Stereotaxis’s moat is not scale. It combines differentiated control physics, clinical experience, regulatory know-how, an installed base, and integration across robot, catheter, and software. The 2025 filing reported 43 issued U.S. patents. Patents matter, but adoption barriers in medical robotics also include physician confidence, hospital workflow integration, training, service capability, and evidence accumulated over many procedures.

Where are the switching costs?

A robotic lab requires capital approval, installation, physician training, staff workflow changes, maintenance, and compatibility with mapping and ablation tools. Once a center builds expertise around the system, switching away can destroy training and process investments. Yet those same requirements also slow new sales. Stereotaxis therefore benefits from switching costs after adoption but must overcome substantial buyer friction before adoption.

What weakens the moat?

Large competitors can spend more on direct sales, clinical studies, reimbursement support, and new ablation modalities. Hospitals may prefer familiar manual systems, and physicians can be reluctant to retrain. The moat is therefore technically meaningful but economically unproven until procedure growth and proprietary-disposable adoption produce sustained gross profit above operating expenses.

Who competes with Stereotaxis, and where does it stand?

Competition extends beyond other robots. Stereotaxis competes with manual catheter navigation, established mapping and ablation ecosystems, pulse-field ablation, pharmaceutical approaches, and alternative robotic systems. Many rivals have larger sales forces and deeper portfolios. Stereotaxis claims a distinctive position in remote, digital control of the catheter working tip, but technical differentiation has not yet produced broad market power.

How should an MBA reader frame its market position?

The trade-off is direct: Stereotaxis must invest enough to convert differentiation into adoption, but each additional commercial or development expense increases financing pressure. Partnerships, reference centers, independent Synchrony placements, and Robocath can expand reach while adding execution complexity.

How strong are the balance sheet and capital allocation?

At March 31, 2026, Stereotaxis held $14.6 million of cash, no debt, and about $12.9 million of working capital. Q1 operating cash outflow was $3.4 million and capital expenditure was $0.1 million, implying approximately $3.5 million of free cash outflow. The main funding burden is operating loss and working capital, not heavy physical investment.

What did FY2025 reveal about operating leverage?

How should capital allocation be judged?

Management is directing capital toward launches, vertical integration, commercial expansion, and Robocath rather than dividends or repurchases. That is coherent for an early-scale robotics company, but every dollar must improve placements, utilization, proprietary-device revenue, or future market access. The acquisition adds another loss-making operation, so milestone conversion matters more than headline opportunity.

Who owns Stereotaxis stock, and how is it governed?

The 2026 proxy reported 97,477,538 common shares outstanding on March 16, 2026, plus 21,008 Series A preferred shares. The preferred stock was convertible into 23,705,445 common shares, subject to beneficial-ownership limits. Economic exposure and potential dilution therefore extend beyond the current common count.

Why does the ownership structure matter?

The 2026 proxy statement describes a staggered board, standing committees, and material equity incentives. Combined with ATM financing and acquisition stock, dilution is a recurring governance and valuation issue.

What opportunities and risks define the next phase?

What could accelerate growth?

GenesisX can reduce installation barriers. Synchrony can enter non-robotic labs. MAGiC can lift disposable revenue per procedure, while Robocath extends the company into coronary and other endovascular interventions. The acquisition announcement cited 15 installed R-One+ systems at April 2026. Commercial expansion is plausible, but management targets remain execution-dependent.

What could weaken the story?

The principal risks are execution and funding. System sales can be delayed by budgets, construction, integration, or training. Catheter production must scale without quality failures, and physicians must adopt new workflows. Stereotaxis also relies on external and sometimes single-source suppliers. Its July 2026 Robocath risk filing said Robocath had historically generated losses and was expected to remain cash-flow negative for several years.

Which KPIs matter most for a Stereotaxis DCF?

A valuation model should separate volatile, lower-margin system placements from recurring economics. Disposable, service, and software revenue should be modeled from installed systems, procedure volume, revenue per procedure, and retention. The core question is whether recurring gross profit can grow faster than sales, research, and corporate costs.

What is the key margin equation?

The key identity is simple: total gross profit equals system gross profit plus recurring gross profit. Because recurring activities carried far higher margins in FY2025, a DCF should emphasize recurring growth and mix, then subtract capital expenditure from operating cash flow and explicitly model financing, acquisition obligations, and dilution.

What is the key takeaway from Stereotaxis analysis?

Stereotaxis is a differentiated medical robotics company at a decisive transition point. Its magnetic navigation platform has clinical history, a specialized installed base, and a distinctive control method. Adding proprietary disposables, software, easier-to-install robots, and Robocath is strategically coherent because each can expand the market or increase recurring procedure revenue.

The finances remain immature. FY2025 revenue grew 20.3% to $32.4 million, yet operating loss was $22.1 million and operating cash outflow was $13.7 million. Q1 2026 revenue then declined 15.8% while gross margin improved to 60.3%. The central question is whether launches can create enough high-margin recurring gross profit before losses, acquisition costs, and dilution consume the benefit.